Sign up to save your podcasts
Or
Share NADIM II & Favorable Risk RCC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NADIM II & Favorable Risk RCC
This episode...
More evidence to support the use of neoadjuvant ICI/chemo in stage III NSCLC to obtain pCR published this week with NADIM II.
Time to rethink giving ICI/TKI combination therapy to favorable-risk metastatic RCC patients? (Finally, I'm not the only one saying this anymore.)
NADIM II: https://www.nejm.org/doi/full/10.1056/NEJMoa2215530
FDA Pooled Analysis Favorable Risk metastatic RCC: https://doi.org/10.1016/j.eururo.2023.05.030
View all episodes
By John Bossaer
4.9
185185 ratings
This episode...
More evidence to support the use of neoadjuvant ICI/chemo in stage III NSCLC to obtain pCR published this week with NADIM II.
Time to rethink giving ICI/TKI combination therapy to favorable-risk metastatic RCC patients? (Finally, I'm not the only one saying this anymore.)
NADIM II: https://www.nejm.org/doi/full/10.1056/NEJMoa2215530
FDA Pooled Analysis Favorable Risk metastatic RCC: https://doi.org/10.1016/j.eururo.2023.05.030
More shows like OncoPharm
View all
JAMA Clinical Reviews
503 Listeners
The Daily
113,450 Listeners
Up First from NPR
56,968 Listeners
Armchair Expert with Dax Shepard
69,625 Listeners
ASCO Guidelines
46 Listeners
The Peter Attia Drive
8,019 Listeners
OncLive® On Air
23 Listeners
Raising Good Humans
1,885 Listeners
Oncology Today with Dr Neil Love
61 Listeners
Huberman Lab
29,253 Listeners
The Money with Katie Show
1,543 Listeners
Two Onc Docs
196 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
46 Listeners
WolverHeme Happy Hour
30 Listeners
Good Hang with Amy Poehler
12,333 Listeners